Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

伊库利珠单抗 阵发性夜间血红蛋白尿 医学 血红蛋白尿 临床终点 溶血 内科学 胃肠病学 随机对照试验 外科 免疫学 补体系统 抗体
作者
Alexander Röth,Guangsheng He,Hongyan Tong,Zenghua Lin,Xiaoqin Wang,Chatree Chai‐Adisaksopha,Je‐Hwan Lee,Andrés Brodsky,Chattree Hantaweepant,Teresita Dumagay,Roberta Demichelis‐Gómez,Ponlapat Rojnuckarin,Jing Sun,Martin Höglund,Jun Ho Jang,Anna Gayà,Fernando Silva,Naoshi Obara,Richard J. Kelly,Leigh Beveridge
出处
期刊:American Journal of Hematology [Wiley]
卷期号:99 (9): 1768-1777 被引量:40
标识
DOI:10.1002/ajh.27412
摘要

Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low-volume self-administration every 4 weeks. COMMODORE 2 (NCT04434092) is a global, randomized, open-label, multicenter, phase 3 trial evaluating the non-inferiority of crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria not previously treated with C5 inhibition. C5 inhibitor-naive patients with lactate dehydrogenase (LDH) ≥2 × upper limit of normal (ULN) were randomized 2:1 to crovalimab or eculizumab. Co-primary efficacy endpoints were proportion of patients with hemolysis control (centrally assessed LDH ≤1.5 × ULN) and proportion with transfusion avoidance. Secondary efficacy endpoints were proportions of patients with breakthrough hemolysis, stabilized hemoglobin, and change in FACIT-Fatigue score. The primary treatment period was 24 weeks. Two hundred and four patients were randomized (135 crovalimab; 69 eculizumab). Crovalimab was non-inferior to eculizumab in the co-primary endpoints of hemolysis control (79.3% vs. 79.0%; odds ratio, 1.0 [95% CI, 0.6, 1.8]) and transfusion avoidance (65.7% vs. 68.1%; weighted difference, -2.8 [-15.7, 11.1]), and in the secondary efficacy endpoints of breakthrough hemolysis (10.4% vs. 14.5%; weighted difference, -3.9 [-14.8, 5.3]) and hemoglobin stabilization (63.4% vs. 60.9%; weighted difference, 2.2 [-11.4, 16.3]). A clinically meaningful improvement in FACIT-Fatigue score occurred in both arms. Complete terminal complement activity inhibition was generally maintained with crovalimab. The safety profiles of crovalimab and eculizumab were similar with no meningococcal infections. Most patients who switched from eculizumab to crovalimab after the primary treatment period preferred crovalimab. These data demonstrate the positive benefit-risk profile of crovalimab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
toot完成签到,获得积分10
1秒前
1秒前
韩晓蕊完成签到,获得积分10
1秒前
2秒前
3秒前
彭于晏的应助被张君采纳,获得10
3秒前
fdl完成签到 ,获得积分10
3秒前
4秒前
哈哈王完成签到,获得积分10
4秒前
落骛发布了新的文献求助30
4秒前
NexusExplorer的应助被吴军霄采纳,获得10
4秒前
4秒前
海哥哥发布了新的文献求助10
5秒前
5秒前
5秒前
YixiaoWang完成签到,获得积分10
6秒前
今后的应助被youkang采纳,获得10
6秒前
tao完成签到,获得积分10
6秒前
6秒前
泽北发布了新的文献求助10
7秒前
长青发布了新的文献求助10
7秒前
周舟完成签到,获得积分10
8秒前
hyl完成签到,获得积分10
8秒前
李健的应助被布洛芬采纳,获得10
8秒前
8秒前
徐枘发布了新的文献求助10
8秒前
10秒前
晶晶完成签到,获得积分0
10秒前
369ninja发布了新的文献求助10
10秒前
JJBOND发布了新的文献求助10
11秒前
隐形曼青的应助被felix采纳,获得10
11秒前
Wonder罗完成签到,获得积分10
12秒前
13秒前
13秒前
xxv发布了新的文献求助10
13秒前
14秒前
CodeCraft的应助被温羞花采纳,获得10
14秒前
余香的应助被wangyongfang采纳,获得10
16秒前
Lu发布了新的文献求助10
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817